Skip to content
CUECue Biopharma, Inc.

Earnings

When Cue Biopharma, Inc. reports, what it reported each quarter, and how the stock took the results.

39 quarters. Mar 31, 2017 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 15, after the close

Mon, Mar 15, 2027in 118 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – Apr 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$21.94M
Revenue, change from a year earlier: Q3 2026 −93.9%, Q2 2026 +166.7%, Q1 2026 +1,250.6%, Q4 2025 +1,292.3%
Net income
$1.59M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$132.00K−93.9% vs Q3 2025

Latest results

  1. Q3 2026Nov 16, 2026, after the closeThe release
    Revenue
    $132.00K
    −93.9%
    Net income
    -$50.02M
    N/M
    EPS
    -$4.74
    N/M
    Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
  2. Q2 2026Aug 14, 2026, after the closeThe release17.0%by the close of Aug 17
    Revenue
    $7.88M
    +166.7%
    Net income
    -$153.07M
    N/M
    EPS
    -$24.14
    N/M
  3. Q1 2026May 14, 2026, after the close8.8%by the close of May 15
    Revenue
    $5.69M
    +1,250.6%
    Net income
    -$5.18M
    N/M
    EPS
    -$1.08
    N/M
  4. Q4 2025Mar 16, 2026, after the closeThe release12.9%by the close of Mar 17
    Revenue
    $21.94M
    +1,292.3%
    Net income
    $1.59M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 16, 2026 · after-hoursNov 16, 202647 d10-Q$132.00K−93.9%-$4.74—
Q2 2026Jun 30, 2026Aug 14, 2026 · after-hoursAug 14, 202645 d10-Q$7.88M+166.7%-$24.1417.0%
Q1 2026Mar 31, 2026—May 14, 202644 d10-Q$5.69M+1,250.6%-$1.088.8%
FY 2025
Q4 2025derivedDec 31, 2025Mar 16, 2026 · after-hoursMar 16, 202675 d10-K$21.94M+1,292.3%—12.9%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 12, 202543 d10-Q$2.15M−35.6%-$2.227.2%
Q2 2025Jun 30, 2025Aug 12, 2025 · after-hoursAug 12, 202543 d10-Q$2.95M+11.1%-$2.670.9%
Q1 2025Mar 31, 2025May 12, 2025 · after-hoursMay 12, 202542 d10-Q$421.00K−75.5%-$4.950.5%
FY 2024
Q4 2024derivedDec 31, 2024Mar 31, 2025 · after-hoursMar 31, 202590 d10-K$1.58M−13.5%—17.7%
Q3 2024Sep 30, 2024Nov 14, 2024 · after-hoursNov 14, 202445 d10-Q$3.34M+58.9%-$0.1716.7%
Q2 2024Jun 30, 2024—Aug 14, 202445 d10-Q$2.66M+92.3%-$0.20+20.6%
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q$1.72M+818.2%-$0.2520.2%
Earlier years, FY 2017 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 16, 2026463755
10-QAug 14, 2026352128
10-QMay 14, 2026224091
10-KMar 16, 2026108287
10-QNov 12, 2025277466
10-QAug 12, 2025107270
10-QMay 12, 2025069125
10-KMar 31, 2025047677
10-QNov 14, 2024127005
10-QAug 14, 2024096967

Provenance

ProvenanceData status and checks

Cue Biopharma, Inc. · CIK 1645460 · Engraved from SEC EDGAR